Department of Vermont Health Access
Pharmacy Benefits Management Program
DUR Board Meeting Agenda

February 19, 2019: 6:30 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**

- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
  (Public Comment Prior to Board Action**)**

- **DVHA Pharmacy Administration Updates** **6:35 - 6:40**

- **Medical Director Update** **6:40 – 6:45**

- **Follow-up Items from Previous Meetings** **6:45 –6:55**
  - Additional data on Vivitrol RetroDUR

- **RetroDUR/ProDUR** **6:55-7:10**
  - Introduce: Evaluation of Opioid Prescribing for Chronic Pain
  - Data presentation: Co-prescribing of Opiates and Benzodiazepines

- **Clinical Update: Drug Reviews** **7:10-7:35**
  (Public comment prior to Board action)

  Abbreviated New Drug Reviews
  None at this time

  Full New Drug Reviews
  - Doptelet® (avatrombopag) (Included in the Platelet Stimulating Agents Therapeutic Drug Class review)
  - Jivi® (recombinat) (Included in the Hemophilia Factor Deficiency Therapeutic Drug Class review)
  - Lokelma® (sodium zirconinum cyclosilcate)
  - Mulpleta® (lusutrombopag) (Included in the Platelet Stimulating Agents Therapeutic Drug Class review)
  - Orilissa® (elagolix)
  - Perseris® (risperidone)
  - Takhzyro® (lanadelumab-flyo) (Included in the Hereditary Angioedema Therapeutic Drug Class review)

- **New Managed Therapeutic Drug Classes** **7:35-7:45**
  (Public comment prior to Board action)
  - Platelet Stimulating Agents

- **Therapeutic Drug Classes – Periodic Review** **7:45 – 8:25**

(Public comment prior to Board action)

- Atopic Dermatitis
- Gaucher Disease
- Hemophilia Factor Deficiency
- Hereditary Angioedema
- Muscular Dystrophy
- Pancreatic Enzymes
- Prenatal Vitamins
- Psoriasis Nonbiologic Oral and Topical

- **Review of Newly-Developed/Revised Criteria** **8:25 – 8:25**
  (Public comment prior to Board action)

- **General Announcements** **8:25 – 8:30**
  Selected FDA Safety Alerts
  FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab)
  https://www.fda.gov/Drugs/DrugSafety/ucm624247.htm?utm_campaign=New%20Drug%20Safety%20Communication%20on%20Lemtrada%20%28alemtuzumab%29-%20Drug%20Information%20Update&utm_medium=email&utm_source=Eloqua

- **Adjourn** **8:30**